Table 2 QOL Results Post SABR to Liver

Thibault [21]

Mean QOL at 1 week, 6 weeks, 3 months, by component

~ No clinically or statistically significant decline in QOL at final endpoint (3 months) in either QOL tool

~ Mostly stable QOL item scores (12/15 in QLQ-C15, 21/21 in QLQ-LM21) in measurements over 12 weeks

~ Increased fatigue, decreased global health status at 1 week post treatment on C15 (p = 0.049, p = 0.033); both returned to baseline at 6 weeks and 3 months

Shun [22]

Mean QOL at 1 week pretreatment, weekly for 6 weeks during

~ Non-clinically and non-statistically significant increase in QOL scores at 6 weeks

~ Mean symptom severity (measured on Symptom Severity Scale) increased at final endpoint

~ Mean depression (measured on POMS-D Depression subscale) increased at final endpoint

~ Functional status (p = 0.003), depression (p = 0.0001), symptom severity significantly (p = 0.0002), level of albumin (p = 0.001) associated with changes in QOL

~ Radiation dosage not significant factor in QOL during treatment

Mendez Romero [20]

~Mean QOL at pretreatment and 1/3/6 month

~Symptom and functional domains

~ No statistically significant decline in mean QOL over 6 months

~ Fatigue at 1 month showed significant decline when compared baseline (p = 0.004); returned to baseline thereafter; was only functional or symptom-specific domain to show significant decline; though trends showed worsening symptoms across time points

~ Non statistically significant trend towards improvement noted at final endpoint

~ Baseline QOL of patients was lower than general population comparison group (p < 0.001)

Klein [18]

~ Mean QOL @ 0 1,3,6,12 months

~ Percent patients where QOL “improved” vs “Stable” vs “Worsened”), (MID = 10 on QLQ C30, vs 14 on FACT-Hep)

~ Beyond 3 months, no significant worsening vs baseline in both tools

~ Using FACT-Hep/QLQ-C30, 54%/48% reported stable QOL, 27%/39% showed clinically significant worsening, 19%/23% showed significant improvement at 12 months post treatment

~ Significant worsening from baseline in appetite (11.7 points) and fatigue (11.0 points) at 1 month, both return to baseline by 3 months on QLQ-C30

~ Other variables show no clinically or statistically significant change from baselines

~ Higher baseline QOL predicts improved survival in both FACT-HEP (p = 0.001) and QLQ-C30 (p = 0.012)

~ LM patients experienced statistically significantly, but not clinically significant, better quality of life at 6 months when compared to HCC (p = 0.04); no difference between LM and IHC, or IHC and HCC patients

Law [19]

Mean QOL @ baseline, post treatment, 3, 6 months

~ MID > 5% change

~ No statistically or clinically significant change in FACT-Hep score in all time points vs baseline, trend towards poorer QOL at final end point (p = 0.09)